What is Converge Bio worth?
$90.0Mlast known valuation
Converge Bio last raised $25.0M in its Early Stage VC (Series A) (Jan 2026).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Converge Bio
Create free account
No card required
Funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jan 2026 | Early Stage VC (Series A) | $25.0M | ▮ | ▮ |
How Converge Bio's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Converge Bio, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- What is Converge Bio worth?
- Converge Bio's last known valuation is $90.0M.
- How much has Converge Bio raised?
- Converge Bio has raised $30.5M in total funding across 1 recorded rounds.
- When did Converge Bio last raise?
- Converge Bio last raised in Jan 2026 (Early Stage VC (Series A)), raising $25.0M.